Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure01:10

Antibody Structure

57.5K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
57.5K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.8K
Antibody Structure and Classes01:25

Antibody Structure and Classes

645
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
645
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Enzyme Inhibition01:30

Enzyme Inhibition

77.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation.

Allergy·2026
Same author

Emerging diagnostic and therapeutic opportunities in food allergy.

Frontiers in immunology·2026
Same author

Novel Biomarkers and Diagnostic Tools in Food Allergy.

Allergy·2025
Same author

High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo.

The Journal of allergy and clinical immunology·2025
Same author

Age-Related Increase in Anaphylaxis Severity Is Associated With Enhanced Sensitivity to Allergic Mediators.

Allergy·2025
Same author

IL-33/ST2 signaling in ILC2s drives exhaustion and myeloid skewing of HSCs in response to hematopoietic stress and aging.

iScience·2025
Same journal

Diversity, Equality, and Inclusion in the naïve T Cell Receptor Repertoire.

Immunological reviews·2026
Same journal

Macrophage Plasticity and Immune Remodeling in Ischemic Heart Failure.

Immunological reviews·2026
Same journal

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.

Immunological reviews·2026
Same journal

Tissue-Resident Memory T Cells in the Heart: An Emerging Role in Chronic Inflammation.

Immunological reviews·2026
Same journal

Rethinking Immunity in Tissues: The Biology of Tertiary Lymphoid Structures.

Immunological reviews·2026
Same journal

Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.

Immunological reviews·2026
See all related articles

Related Experiment Video

Updated: May 9, 2025

Detection of True IgE-expressing Mouse B Lineage Cells
09:40

Detection of True IgE-expressing Mouse B Lineage Cells

Published on: December 1, 2014

10.9K

Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition.

Alexander Eggel1,2, Theodore S Jardetzky3

  • 1Department for BioMedical Research, University of Bern, Bern, Switzerland.

Immunological Reviews
|April 30, 2025
PubMed
Summary
This summary is machine-generated.

New therapies targeting immunoglobulin E (IgE) leverage its unique structural flexibility to disrupt allergic reactions. These advanced biologics offer faster and broader treatment for allergies by targeting both free and bound IgE.

Keywords:
CD23DARPinsFcεRI⍺IgEIgE receptorsallergydisruptive IgE inhibitorsfacilitated dissociationligelizumabomalizumab

More Related Videos

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

1.6K
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.1K

Related Experiment Videos

Last Updated: May 9, 2025

Detection of True IgE-expressing Mouse B Lineage Cells
09:40

Detection of True IgE-expressing Mouse B Lineage Cells

Published on: December 1, 2014

10.9K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

1.6K
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.1K

Area of Science:

  • Immunology
  • Structural Biology
  • Allergy Research

Background:

  • Immunoglobulin E (IgE) is crucial for defense but central to allergic reactions.
  • IgE interacts with FcεRI and CD23 receptors on immune cells, amplifying type 2 immunity.
  • IgE's conformational flexibility dictates receptor binding and function.

Purpose of the Study:

  • To review how structural and mechanistic insights into IgE and its receptors inform next-generation anti-IgE therapies.
  • To highlight the development of "disruptive" IgE inhibitors that disassemble IgE:FcεRI complexes.
  • To discuss the potential of these new biologics for faster and more effective allergy treatment.

Main Methods:

  • Analysis of structural studies on IgE conformations and receptor interactions.
  • Review of existing anti-IgE biologics (e.g., omalizumab) and their limitations.
  • Examination of novel "disruptive" IgE inhibitors and their mechanisms of action.

Main Results:

  • IgE adopts distinct conformations (open/closed) for selective FcεRI or CD23 binding.
  • Current anti-IgE therapies primarily neutralize free IgE, with limitations in targeting bound IgE.
  • New "disruptive" inhibitors actively disassemble IgE:FcεRI complexes, enabling rapid desensitization.

Conclusions:

  • Understanding IgE conformational dynamics is key to designing advanced anti-IgE therapeutics.
  • Next-generation "disruptive" IgE inhibitors offer potential for faster onset and broader efficacy.
  • These multifunctional biologics represent a new era in IgE-targeted allergy therapy.